CD4+/CD56+ Hematodermic Tumor
Marco Herling(Unknown), Dan Jones(The Ohio State University Wexner Medical Center)
Cited by 172
Related Papers
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
|Leukemia|2006|387
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
|Blood|2019|161
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL
|Nature Communications|2018|105